AMARIN CORP PLC\UK Proceeds from Issuance of Private Placement
AMARIN CORP PLC\UK (AMRN) reported Proceeds from Issuance of Private Placement of $52.80 million for the 12-month period ending 2015-12-31, per its 10-K filed 2016-02-25.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfPrivatePlacement · last filed 2020-11-05
- AMARIN CORP PLC\UK proceeds from issuance of private placement for the quarter ending 2015-12-31 was $0.00.
- AMARIN CORP PLC\UK proceeds from issuance of private placement for the quarter ending 2015-09-30 was $0.00.
- AMARIN CORP PLC\UK proceeds from issuance of private placement for the quarter ending 2015-06-30 was $0.00.
- AMARIN CORP PLC\UK proceeds from issuance of private placement for the quarter ending 2015-03-31 was $52.80M.
- AMARIN CORP PLC\UK proceeds from issuance of private placement for fiscal 2015 was $52.80M.
| Period end | Proceeds from Issuance of Private Placement 3 month | Proceeds from Issuance of Private Placement 6 month | Proceeds from Issuance of Private Placement 9 month | Proceeds from Issuance of Private Placement 12 month |
|---|---|---|---|---|
| 2015-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-25 | $0.00 derived: sum of 2 quarters · filed 2016-02-25 | $0.00 derived: sum of 3 quarters · filed 2016-02-25 | $52.80M 10-K · filed 2016-02-25 |
| 2015-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-04 | $0.00 derived: sum of 2 quarters · filed 2015-11-04 | $52.80M 10-Q · filed 2015-11-04 | |
| 2015-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-06 | $52.80M 10-Q · filed 2015-08-06 | ||
| 2015-03-31 | $52.80M 10-Q · filed 2020-11-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B |